Literature DB >> 2788058

Use of high-dose intravenous immunoglobulin in systemic lupus erythematosus: report of three cases.

A Corvetta1, R Della Bitta, A Gabrielli, P J Spaeth, G Danieli.   

Abstract

Three patients with life-threatening manifestations of systemic lupus erythematosus (SLE), unresponsive to conventional high-dose corticosteroid and/or immunosuppressive therapy were treated with intravenous polyspecific IgG (IVIG). Following IVIG infusion, lupus encephalitis in the first patient quickly resolved and the impressive improvement of the clinical status was associated with a transient increase in C1q-binding activity. The daily infusion of IgG had to be suspended after three days in the second patient with encephalitis and nephritis, because the renal function rapidly deteriorated; subsequently, six plasma exchanges led to an almost complete recovery. Finally, leukocyte and platelet counts increased and remained within normal range following IgG therapy in the third patient having SLE-associated leuko- and thrombocytopenia. In all three patients a decrease in anti-DNA antibody levels and an increase in total complement hemolytic activity were detected after therapy.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2788058

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  11 in total

Review 1.  Immunomodulation of autoimmune diseases by high-dose intravenous immunoglobulins.

Authors:  L Rauova; J Rovensky; Y Shoenfeld
Journal:  Springer Semin Immunopathol       Date:  2001-12

Review 2.  Rheumatology.

Authors:  R A Asherson; R Cervera; D P D'Cruz; G R Hughes
Journal:  Postgrad Med J       Date:  1991-02       Impact factor: 2.401

Review 3.  Intravenous immunoglobulin therapy and systemic lupus erythematosus.

Authors:  Gisele Zandman-Goddard; Yair Levy; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

Review 4.  Intravenous immunoglobulins for treatment of connective tissue diseases in dermatology.

Authors:  Lyubomir A Dourmishev; Dimitrina V Guleva; Ljubka G Miteva
Journal:  Wien Med Wochenschr       Date:  2017-09-01

Review 5.  Pharmacokinetic modeling of therapies for systemic lupus erythematosus.

Authors:  Xiaoyan Yang; Catherine M T Sherwin; Tian Yu; Venkata K Yellepeddi; Hermine I Brunner; Alexander A Vinks
Journal:  Expert Rev Clin Pharmacol       Date:  2015-07-09       Impact factor: 5.045

Review 6.  Treatment of autoimmune diseases and systemic vasculitis with pooled human intravenous immune globulin.

Authors:  S C Jordan; M Toyoda
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

Review 7.  Treatment of acute neuropsychiatric lupus with intravenous immunoglobulin (IVIG): a case report and review of the literature.

Authors:  Aaron M Milstone; Kevin Meyers; Josephine Elia
Journal:  Clin Rheumatol       Date:  2005-01-21       Impact factor: 2.980

Review 8.  The role of IVIG in the management of patients with antiphospholipid antibodies and recurrent pregnancy losses.

Authors:  A Parke
Journal:  Clin Rev Allergy       Date:  1992 Spring-Summer

Review 9.  Adverse effects of intravenous immunoglobulin.

Authors:  S A Misbah; H M Chapel
Journal:  Drug Saf       Date:  1993-10       Impact factor: 5.606

10.  Intravenous immunoglobulin in the management of lupus nephritis.

Authors:  Scott E Wenderfer; Trisha Thacker
Journal:  Autoimmune Dis       Date:  2012-09-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.